Intellectual Property

  • July 15, 2026

    Copyright Office Revises Fee Hikes After Public Comments

    The U.S. Copyright Office has backed away from eliminating its lowest-cost basic registration option and trimmed three other proposed fee hikes after public comments, while preserving most of the broader fee overhaul it unveiled in March.

  • July 14, 2026

    White House Unveils New AI Cybersecurity Clearinghouse

    The White House has launched a clearinghouse for both the government and the private sector that's aimed at identifying and patching cyber vulnerabilities using artificial intelligence, according to an announcement made Tuesday.

  • July 14, 2026

    Sanofi Says Pfizer, Moderna COVID Jabs Infringe MRNA Tech

    Sanofi's pharmaceutical and therapeutics subsidiaries say the COVID-19 vaccines that have netted Pfizer and Moderna billions of dollars infringe their patents covering mRNA technology, according to a pair of lawsuits filed Tuesday in New Jersey federal court.

  • July 14, 2026

    DOJ Drops Trade Secrets Case Against DuPont Rival Mid-Trial

    Just a few days into the start of a monthlong trial, the U.S. Department of Justice has dropped its 15-year-old criminal espionage case alleging a group of related Chinese steel companies stole DuPont Co. trade secrets for creating titanium dioxide.

  • July 14, 2026

    Coinbase Wants Texas Court To Toss Blockchain Patent Suit

    Coinbase Global Inc. asked a Texas federal judge to toss claims alleging the company infringed a group of patents covering improvements to blockchain technology, saying the asserted patents violate "bedrock principles of patent eligibility."

  • July 14, 2026

    9th Circ. Erases Comet's $40M Trade Secret Verdict

    A split Ninth Circuit panel on Tuesday overturned Comet Technologies USA's $40 million trade secret verdict against XP Power and ordered a new trial, holding in a precedential decision that the jury was wrongly instructed that XP had to prove Comet's claimed secrets could have been lawfully discovered or reverse-engineered.

  • July 14, 2026

    USPTO Decries Arbitrator's 'Extreme' Mgmt Rights Threat

    The U.S. Patent and Trademark Office has pushed back on an arbitrator holding that the agency violated union agreements when ending telework arrangements, saying the arbitrator ignored management rights provisions and added her own terms to the contract.

  • July 14, 2026

    Centripetal Seeks Squires Reversal Of Cisco Patent Win

    Centripetal Networks has asked U.S. Patent and Trademark Office Director John Squires to undo a Patent Trial and Appeal Board decision invalidating its cybersecurity patent at issue in a since-vacated multibillion-dollar judgment against Cisco Systems, saying the ruling flouted the law.

  • July 14, 2026

    Patent Eligibility Bill Divides Senators Over Health Costs

    Several U.S. senators expressed strong support at a hearing Tuesday for a bill aimed at expanding which inventions are eligible for patents, while others appeared to have reservations about the potential effect of the proposed changes on healthcare costs.

  • July 14, 2026

    Bayer Defends Fees For Seed Tech With Expired Patents

    Bayer asked a Missouri federal judge to dismiss a sweeping antitrust proposed class action, arguing that the independent seed company suing it, in a complaint that also includes breach of contract allegations, is contesting perfectly legal licensing fees charged for corn technology, even after the last patents expired.

  • July 14, 2026

    Google Judge Streamlines Voice Assistant Tech Antitrust Suit

    Software developer Sensory can pursue antitrust claims alleging Google illegally maintains monopolies over voice assistant and similar technology markets, but not its broader claims involving the general search and advertising markets, a Washington, D.C., federal judge ruled.

  • July 14, 2026

    Alex Jones' Co. Balks At Sandy Hook Victims' Stay Appeal

    Right-wing conspiracy theorist Alex Jones' media company has urged the Texas Supreme Court to reject a bid by victims of the Sandy Hook Elementary School shooting to license his website, Infowars, to The Onion, arguing the request is defective and the satire publication is already damaging the brand.

  • July 14, 2026

    Former Deputy Patent Commissioner Kim Joins Jones Day

    A newly departed U.S. Patent and Trademark Office deputy commissioner with a strong background in artificial intelligence has joined Jones Day as a partner in its global intellectual property practice, the firm said Tuesday.

  • July 14, 2026

    Google Is Wrong, 'Settled Expectations' Is Legal, Justices Told

    Software company VirtaMove has argued that the U.S. Supreme Court should ignore Google's challenge to the U.S. Patent and Trademark Office's policy of using the age of patents as a reason to not review them, saying Google's fight is based on a false foundation.

  • July 14, 2026

    Gov't Shouldn't Face Vax Suit Targeting Moderna, Group Says

    Conservative advocacy organization Eagle Forum Education & Legal Defense Fund on Tuesday urged the Federal Circuit to reject a proposal to shift a multibillion-dollar patent infringement case over the COVID-19 vaccine that is targeting Moderna to the federal government, saying doing so would reduce the crucial economic incentives that power innovation in the pharmaceutical industry.

  • July 14, 2026

    Iowa Lacks Ties To Starbucks IP Fight, Workers United Says

    Starbucks Workers United has asked an Iowa federal judge to dismiss claims accusing the union of infringing the coffee chain's trademarks through its name and logo, arguing the dispute does not belong in Iowa federal court.

  • July 14, 2026

    10th Circ. Revives False Ad Claims Against Hill's Pet Food

    The Tenth Circuit on Tuesday revived part of a proposed class action accusing a pet food maker of falsely claiming a link between grain-free dog food and canine heart disease, holding that some of its webpages and veterinary education materials could be viewed as promoting its grain-based products through unsupported scientific claims.

  • July 14, 2026

    Senate Finance Committee Approves ITC Commissioner Picks

    The Senate Finance Committee approved five nominees to serve as commissioners for the U.S. International Trade Commission on Tuesday.

  • July 14, 2026

    Fed. Circ. Won't Revive Eyewear Tech Patent Claims

    The Federal Circuit on Tuesday shot down an attempt to bring back claims in a patent covering a sensor in eyewear meant to detect human eye movement, affirming a Patent Trial and Appeal Board decision that the claims were obvious.

  • July 14, 2026

    Quinn Emanuel, Spiro Ousted From CoStar Copyright Fight

    A California federal judge has disqualified Quinn Emanuel Urquhart & Sullivan LLP and its attorney Alex Spiro from representing a commercial real estate platform in a copyright infringement suit brought by CoStar, agreeing that the firm's representation of CoStar in a different case should result in its removal from this one.

  • July 14, 2026

    Insurer Ducks Models' Advertising Claims Against Strip Club

    A Connecticut federal judge has handed Clear Blue Specialty Insurance Co. a win in six professional models' attempts to access a strip club's $1 million policy pursuant to a settlement in an underlying false association and false advertising lawsuit, saying an exclusion for "exhibitions and related marketing" insulates the insurer.

  • July 14, 2026

    Google Faces Another AI Copyright Suit By Publishers

    Book publishers and legal novelist Scott Turow have lodged a copyright infringement suit alleging Google used their works to train its artificial intelligence model Gemini following an earlier suit they launched against Meta.

  • July 14, 2026

    Pharma Cos. Clash In Del. Chancery Over Dental Drug License

    Ventis Pharma Inc. has sued Balanced Pharma Inc. in the Delaware Chancery Court, accusing its licensee of failing to make commercially reasonable efforts to develop and market a licensed dental anesthetic product and seeking a declaration that the companies' exclusive licensing agreement has been terminated.

  • July 14, 2026

    AstraZeneca To Acquire Lung Cancer Drug License For $1.5B

    Multinational pharma giant AstraZeneca said Tuesday that it has agreed to acquire worldwide rights to develop and commercialize a lung cancer drug for as much as $1.5 billion from Chinese pharma company Dizal Pharmaceutical Co. Ltd.

  • July 13, 2026

    Portofino Says Citadel Used Dismissal To Fuel Press Campaign

    Portofino Technologies has accused Citadel Securities of using its decision to drop its trade secrets lawsuit against the Swiss cryptocurrency trading firm as an opportunity to drum up bad press about Portofino, and papering over the fact that an $8 million judgment it won in the dispute is a "pyrrhic victory."

Expert Analysis

  • Reel Justice: 'Obsession' And The Importance Of Precision

    Author Photo

    In “Obsession,” the main character’s failure to define the limits of his wish result in an unexpectedly horrifying outcome, highlighting for attorneys why careful word choice is essential not only in briefs, but also in charging decisions, statutory interpretation and all stages of criminal litigation, says Veronica Finkelstein at Widener-Delaware Law.

  • How Pfizer Won Fed. Circ. Patent Dispute By 1 Carbon Atom

    Author Photo

    The Federal Circuit's recent refusal to revive a patent in Enanta Pharmaceuticals v. Pfizer over an alleged typo creating a one-atom difference in a COVID-19 treatment application hands defendants a template for potentially converting a triable fact question into an early dispositive ruling, say attorneys at Polsinelli.

  • Fed. Circ. Ruling Highlights The Cost Of Incorrect Inventorship

    Author Photo

    The Federal Circuit's recent decision in Fortress Iron v. Digger Specialties, affirming that a fencing company's patents were invalid due to a missing co-inventor, is a reminder that confirming correct inventorship should be a critical part of every patent invalidity workup, say attorneys at Neal Gerber.

  • Shopify Settlement Clouds Open-Source Copyright Limits

    Author Photo

    Shopify's confidential copyright settlement with Shopline, which agreed to stop distributing a disputed storefront theme, raises questions about how far copyright law can protect open-source software without undermining the collaboration that drives development, says Lindsey Sasson at Hach Rose.

  • What Data Says About Biologics-Related Ex Parte Challenges

    Author Photo

    An analysis of the 67 ex parte reexaminations used to challenge biologics patents over the last 13 years reveals that reexamination may emerge as an alternative to inter partes review and postgrant review, despite facing a number of procedural disadvantages, say attorneys at Steptoe.

  • CFIUS' Mandate Misses Foreign Risk In Project Subcontracts

    Author Photo

    Recent calls for the Committee on Foreign Investment in the United States to review equity transactions like the Paramount Skydance-Warner Bros. deal miss a consequential oversight gap — CFIUS' inability to review the subcontracting layer of U.S. infrastructure projects, says Thibaut Giret at Alstef Group.

  • Looking At Drake's Diss Track Appeal Through An IP Lens

    Author Photo

    Though Drake's pending Second Circuit appeal over UMG's promotion of Kendrick Lamar's "Not Like Us" is formally about defamation, it shows that IP considerations can help identify records showing how a work traveled, which may guide courts when deciding context, says attorney Abdul Abdullahi.

  • Series

    Bass Fishing Makes Me A Better Lawyer

    Author Photo

    Landing a trophy striped bass and closing a big deal both require cultivating the patience to finesse — not force — your way to desired outcomes, changing course when your old approach isn’t working and learning from the ones that got away, says Jon Ruiss at Alston & Bird.

  • Roundup

    The Most Talked-About Supreme Court Decisions Of 2026

    Author Photo

    This term, 11 U.S. Supreme Court decisions quickly became hot topics among Law360's guest writers.

  • Fighting The Evidentiary Risks Of Deepfakes In Court

    Author Photo

    Though courts and federal rules are only slowly developing frameworks for assessing digital evidence that could have been created or generated by artificial intelligence, litigators should understand what steps they'll likely need to take to successfully challenge potentially deepfaked exhibits — and fight questions about the authenticity of their own, say attorneys at MoFo.

  • Coordinating Life Sciences IP Strategies In The US And EU

    Author Photo

    As postgrant practice for life sciences patents is restructured in the U.S. and European Union simultaneously, patent owners will need to implement transatlantic coordination that treats international proceedings as components of a single intellectual property risk architecture, says Paul Calvo at Sterne Kessler.

  • Trademark Law As A Tool To Bolster NIL Rights Against AI

    Author Photo

    The meteoric rise of artificial intelligence-generated deepfakes is prompting high-profile celebrities to protect their name, image and likeness rights using federal trademark law — a powerful yet limited supplement to traditional NIL claims, says Susan Natland at BakerHostetler.

  • 'Tiger King' Funeral Clip Ruling Offers Fair Use Road Map

    Author Photo

    The Tenth Circuit's decision in Whyte Monkee v. Netflix that the streaming service's use of another party's funeral footage in the docuseries "Tiger King" constituted fair use lays out a framework for producers to apply the four statutory fair use factors to their own projects, says Frank D’Angelo at Loeb & Loeb.

  • Quantum Readiness May Paradoxically Raise Contractor Risk

    Author Photo

    The organizations best positioned for the cryptographic system migration deadlines and other requirements under President Donald Trump’s recent quantum executive orders will be those able to inventory their cryptographic dependencies while protecting their vulnerability road map from adversaries, says Jesse Lemon at The Beckage Firm.

  • Why Biotech Cos. Need Litigation Plans Before Bad News

    Author Photo

    Biotech companies should take proactive steps to respond to the growing trend of securities litigation filed against them, due to the inherently uncertain nature of their business models and heightened scrutiny of clinical trial disclosures, regulatory communications and investor-facing statements, says Wesley Horton at FBFK.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here